human peripheral blood mononuclear cells, PBMC, MNCs

Human Normal Peripheral Blood Mononuclear Cells (PBMC)

  • $109.00

Get a Quote

Human Peripheral Blood Mononuclear Cells (PBMCs) are blood cells with a single round nucleus. These cells include lymphocytes (T, B and NK cells), monocytes and dendritic cells.  PBMCs are parts of the immune system which are critical to cell-mediated and humoral immunity.

Our Human PBMCs are isolated from normal healthy donor leukopaks collected in acid-citrate-dextrose formula A (ACDA) as an anticoagulant. All donors must be tested negative for HBV, HCV, HIV and Syphilis and are IRB consented.

healthy peripheral blood mononuclear cells, PBMC, MNCs
Peripheral blood mononuclear cells (PBMCs) are purified by a density gradient centrifugation (Ficoll-Paque) and are available in fresh and frozen (cryopreserved) format.  HumanCells' PBMC are isolated from Leuko Pak (Apheresis-derived) which are highly purified, containing a more pure population of mononuclear cells with higher viability when compared to buffy coat derived cells.

Storage Condition

Cryopreserved PBMCs can be stored in Liquid Nitrogen vapor phase for long-term storage.  Storage in liquid phase nitrogen is NOT recommended. Short-term storage of cells (less than 2 weeks) at -80°C is acceptable but should be minimized to ensure maximum stability. Once thawed, samples must be used immediately, and can not be frozen again.

Also available from  Fisher Scientific, human PBMC

Fisher Catalog No.:  

  • NC1681388 (Frozen, 10 million, Cat#: PBMC-C10M)
  • NC1814842 (Frozen, 20 million, Cat#: PBMC-C20M)
  • NC2110997 (Fresh, 50 million, Cat#: PBMC-F50M)
  • NC1814844 (Frozen, 100 million, Cat#: PBMC-C100M)
  • NC2101392 (Fresh, 100 million, Cat#: PBMC-F100M)
  • NC2101862 (Fresh, 300 million, Cat#: PBMC-F300M)
  • NC2101863 (Fresh, 500 million, Cat#: PBMC-F500M)
  • NC2101866 (Fresh, 2 billion, Cat#: PBMC-F2B)
  • NC2101868 (Fresh, 4 billion, Cat#: PBMC-F4B)

Our Product was utilized in:

  • Wu, Kerui, et al. "Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence." Science Advances 9.17 (2023): eade0625.
  • Mao, Chengqiong, et al. "Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression." Science translational medicine 14.648 (2022):DOI:10.1126/scitranslmed.abh1261

    We Also Recommend